Recently, British medical technology company Creavo Medical Technologies announced that it will expand its financing by US$17.5 million. The investors will be jointly led by IP Group plc and Coutts Private Bank. Other investors include the original shareholder University of Leeds (Leeds University, UK) and Europe. And new shareholders of China's private equity institutions Parkwalk Advisors and Puhua Capital Ltd (Puhua Capital). The investment will continue to be used to support Creavo's business strategy, team building, and to promote its proprietary medical diagnostics technology, the Magnetocardiogram (MCG). Founded in 2014, Creavo specializes in the commercial development of advanced sensing technologies for biomagnetic images of human organs for the detection and display of organ magnetic images to aid in disease diagnosis. This organ magnetic map sensing technology is the result of 10 years of research through the team of professors of the University of Leeds, Varcoe. Its core patented product is an electrocardiographic device that can be deployed urgently to detect, display and store electromagnetic fluctuations caused by cardiac activity by detecting magnetic heart maps (MCG). (Source: Creavo Official YouTube) This technology meets the clinical emergency needs of global heart disease and helps doctors quickly screen for severe heart attack signals when patients are admitted to hospital. Early identification and diagnosis of heart attack can reduce patient anxiety, win the best rescue opportunity, reduce bed-ridden hospitalization, and save medical resources. The device will ease UK health care system spending and is expected to save £200 million annually. In addition to emergency screening diagnostic applications in the emergency department, the device has a number of other potential applications, such as analysis for predicting sudden cardiac arrhythmia, as well as for the diagnosis of other organ diseases. “The participation of prominent investors such as Parkwalk Advisors and Puhua Capital represents a high level of recognition for our company's business strategy, team and technology,†said Mr. Robert Barr, Chairman of Creavo. He said that Creavo will continue to promote the commercialization of patented technology, with the immediate goal of achieving a European listing. They will promote relevant clinical research in the UK and plan to develop US market operations and related clinical research. Reference material [1] UK Medtech Creavo Snags $17.5 Million for Heart Attack Test [2] Creavo Medical Technologies' official website Source: Chuangjianhui (WeChat: Inno_Insight) Fire Fighting Boots,Rubber Fire Fighting Boots,Firefighter Work Boots,Firefighter Duty Boots NINGBO TOMAN IMP. & EXP. CO., LTD , https://www.tdotmfiresolution.com
ECG OUT? The magnetocardiogram is coming! Save 200 million pounds of medical insurance every year
:2017-07-18